市场调查报告书
商品编码
1467955
RNA 治疗市场:按技术、适应症和最终用户划分 - 2024-2030 年全球预测RNA Therapy Market by Technology (Enabled Technologies, Enabling Technologies), Indication (Cancer, Cardiovascular, Genetic Disorders), End User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
预计2023年RNA治疗市场规模为21.8亿美元,预计2024年将达26亿美元,2030年将达89.8亿美元,复合年增长率为22.38%。
RNA 疗法涉及利用核糖核酸 (RNA) 分子靶向特定基因序列或细胞机制的治疗方法的开发和商业化。这些治疗方法透过靶向 RNA 分子来取代缺陷基因、抑制有害基因表现或调节细胞功能来治疗多种疾病和病症。对生物技术新兴企业的投资增加、学术界和工业界参与者之间不断加强的合作以及针对未满足的医疗需求不断扩大的潜在治疗标靶组合正在推动对 RNA 疗法的需求。孤儿药认定和加速核准等有利的监管政策加速了多种基于 RNA 的治疗方法的临床开发。与体内 RNA 分子的不稳定性和快速降解相关的递送挑战正在阻碍市场成长。製药公司在利用最尖端科技对治疗选择有限的罕见疾病进行新型 RNA 疗法方面不断取得进展,预计将为市场成长创造机会。
主要市场统计 | |
---|---|
基准年[2023] | 21.8亿美元 |
预测年份 [2024] | 26亿美元 |
预测年份 [2030] | 89.8亿美元 |
复合年增长率(%) | 22.38% |
技术:对可用技术的需求不断增长将推动 RNA 疗法的进步。
透过提供精确操纵 RNA 分子并将其递送至目标细胞所需的工具,可用技术将加速 RNA 治疗的进步。该技术透过将小干扰 RNA (siRNA) 引入细胞来定序特定基因。实行技术透过提供改进的设计、合成、修饰和传递 RNA 分子的方法来促进实行技术的开发和应用。 RNA干扰(RNAi)、反义寡核苷酸 (ASO) 和信使核糖核酸 (mRNA) 疗法等技术提供了根据目标疾病机制调节基因表现的不同方法。
适应症 RNA 疗法在遗传和癌症疾病方面的广泛应用。
RNA疗法透过针对特定的癌基因和抑癌基因,在癌症治疗中极为重要。这些治疗方法有助于控制癌细胞中经常被破坏的基因表现。基于需求的癌症 RNA 治疗偏好包括根据患者基因组成量身定制的个人化治疗。 RNA疗法透过调节疾病相关基因的表达,在治疗心臟衰竭和高血压等心血管疾病方面具有潜在的应用。患有严重或罕见心血管疾病的患者可能会受益于这种标靶治疗,因为它们比传统治疗方法副作用更少且更有效。 RNA疗法可用于治疗单一基因突变或缺陷引起的遗传性疾病。这种基于需求的优先重点是针对患有罕见且危及生命的遗传性疾病且治疗选择有限的患者。 RNA 疗法可以透过调节宿主的免疫反应或直接针对病原体来对抗病毒和细菌感染,例如 COVID-19、B型肝炎和结核病。优先考虑抗药性感染疾病患者和感染疾病期间需要快速反应的患者。 RNA疗法透过针对参与肾功能和纤维化的特定基因,为多囊性肾病变和糖尿病肾臟病等慢性肾臟病提供了新的治疗选择。 RNA疗法有潜力透过调节参与葡萄糖和脂质代谢的关键基因来治疗肥胖、非酒精性脂肪性肝炎(NASH)和第2型糖尿病等代谢性疾病。除了癌症疫苗之外,RNA疗法还用于透过编码患者特异性肿瘤抗原来开发针对各种肿瘤类型的个人化免疫疗法。这种基于需求的偏好针对的是对标准治疗方法反应不佳的侵袭性或转移性癌症患者。 RNA疗法可以透过将受影响基因的功能副本直接传递到视网膜细胞中来帮助治疗由基因突变引起的视网膜疾病,例如莱伯氏先天性黑朦症和老龄化黄斑部病变。
最终用户:学术研究越来越重视推动诊断和药物开发的新发现。
学术研究主要使用RNA疗法来了解基因功能和调控。研究人员采用了多种 RNA 治疗方法,包括小干扰 RNA (siRNA)、反义寡核苷酸 (ASO)、微型RNA(miRNA) 和传讯RNA(mRNA) 疗法。基于 RNA 的诊断着重于透过标靶序列测定和基因表现检测疾病特异性生物标记。与传统的基于 DNA 的方法相比,这些诊断方法提高了灵敏度。 RNA 标靶药物的发现和开发涉及识别新的治疗标靶、设计选择性 RNA 结合小分子或寡核苷酸以及开发创新的递送系统来克服细胞损伤。
区域洞察
美洲 RNA 治疗市场得到发达的医疗保健部门和政府支持计划的支持,美国和加拿大的尖端 RNA 疗法已实现显着商业化,南美国家的製药业正在发展。美洲各国政府鼓励技术进步和研究工作,以为人民提供更好的医疗保健系统,并为整体经济成长和公共福祉做出贡献。日本、印度、中国和韩国等亚太地区新兴经济体和已开发经济体的政府正在鼓励 RNA 疗法的研究和开发。随着新设备和技术迅速商业化并被接受,RNA 疗法在欧洲已广泛采用,医疗保健专业人员也能使用 RNA 疗法。同时,欧洲人口老化正在迅速加剧,多种感染疾病和慢性病的适应症预计将增加。根据人口研究所(PRB)的数据,俄罗斯、德国、义大利、法国、英国、西班牙、土耳其、乌克兰、波兰、奈及利亚和伊朗是65岁及以上人口比例最高的国家。由于欧洲人口老化和残疾征兆像日益增多,需要有效的 RNA 疗法。
FPNV定位矩阵
FPNV定位矩阵对于评估RNA治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对 RNA 治疗市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.RNA治疗市场的市场规模与预测是多少?
2.RNA治疗市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些?
3.RNA治疗市场的技术趋势和法规结构是什么?
4.RNA治疗市场主要厂商的市场占有率为何?
5.进入RNA治疗市场的合适型态和策略手段是什么?
[187 Pages Report] The RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024, at a CAGR 22.38% to reach USD 8.98 billion by 2030.
RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 2.18 billion |
Estimated Year [2024] | USD 2.60 billion |
Forecast Year [2030] | USD 8.98 billion |
CAGR (%) | 22.38% |
Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
Enabled technology drives the advancement in RNA therapy as it provides the tools necessary for precisely manipulating and delivering RNA molecules to target cells. This technology silences specific genes by introducing small interfering RNAs (siRNAs) into cells. Enabling technologies facilitate the development and application of enabled technologies by providing improved RNA molecule design, synthesis, modification, and delivery methods. Enabled technologies such as RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and messenger Ribonucleic Acid (mRNA) therapeutics offer different approaches to modulating gene expression depending on the targeted disease mechanism.
Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
RNA therapy is crucial in cancer treatment by targeting specific oncogenes or tumor suppressor genes. These therapies help to regulate gene expression, which is often disrupted in cancerous cells. Need-based preference for RNA therapy in cancer includes personalized treatments tailored to the patient's genetic makeup. RNA therapy has potential applications for treating cardiovascular diseases such as heart failure and hypertension by modulating the expression of disease-related genes. Patients with severe or rare cardiovascular conditions may benefit from these targeted therapies as they offer fewer side effects and better efficacy compared to conventional treatments. RNA therapy can be used to treat genetic disorders caused by mutations or deficiencies in single genes. This need-based preference focuses on patients with rare, life-threatening genetic diseases with limited treatment options. By modulating host immune responses or directly targeting pathogens, RNA therapy can help combat viral and bacterial infections such as COVID-19, hepatitis B, and tuberculosis. Preference exists for patients suffering from drug-resistant infections or requiring rapid response treatments during outbreaks. RNA therapy provides new treatment options for chronic kidney diseases such as polycystic kidney disease and diabetic nephropathy by targeting specific genes involved in renal function and fibrosis. RNA therapy has the potential to treat metabolic disorders, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes by regulating key genes involved in glucose and lipid metabolism. In addition to cancer vaccines, RNA therapy is used to develop personalized immunotherapies for various tumor types by encoding patient-specific tumor antigens. This need-based preference targets patients with aggressive or metastatic cancers that do not respond well to standard treatments. RNA therapy helps to treat retinal diseases caused by genetic mutations, such as Leber's congenital amaurosis and age-related macular degeneration, by delivering functional copies of the affected genes directly into retinal cells.
End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
In academic research, RNA therapy is primarily utilized for understanding gene function and regulation. Researchers employ various RNA therapeutic approaches such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and messenger RNA (mRNA) therapeutics. RNA-based diagnostics focuses on detecting disease-specific biomarkers through targeted sequencing or gene expression profiling. These diagnostic methods offer increased sensitivity compared to traditional DNA-based techniques. RNA-targeted drug discovery and development involve identifying novel therapeutic targets, designing selective RNA-binding small molecules or oligonucleotides, and developing innovative delivery systems to overcome cellular barriers.
Regional Insights
The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the RNA Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the RNA Therapy Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Therapy Market?
3. What are the technology trends and regulatory frameworks in the RNA Therapy Market?
4. What is the market share of the leading vendors in the RNA Therapy Market?
5. Which modes and strategic moves are suitable for entering the RNA Therapy Market?